Cryopyrin-Associated Periodic Syndromes (CAPS)
2
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
SandozAustria - Kundl
1 programClinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) PatientsN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
HandokHL2351
Akros PharmaJTE-162
SandozClinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients
Clinical Trials (3)
Total enrollment: 301 patients across 3 trials
Phase 2Terminated
Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)
Start: Feb 2026Est. completion: Dec 20265 patients
Phase 1Recruiting
Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients
Start: Nov 2009Est. completion: Dec 2015288 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 301 patients
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.